Through previous literature, investigators found that intervention with nutritional supplements may help to improve cognitive performance and reduce the severity of memory impairment in adults with Alzheimer disease.
1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted in moderately less decline in cognitive and functional measures at 18-month follow-up as compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Rates of Alzheimer’s disease are increasing annually, introducing a considerable burden to
1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted in moderately less decline in cognitive and functional measures at 18-month follow-up as compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Rates of Alzheimer’s disease are increasing annually, introducing a considerable burden to